By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Pharmaceutica N.V. 

Turnhoutseweg 30

Beerse  Antwerpen  2340  Belgium
Phone: 32-14602226 Fax:




Vertex  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Company News
Genometry Announces Deal With Janssen Pharmaceutica N.V. For Library-Scale Gene-Expression Profiling 10/8/2015 11:41:26 AM
Royal Philips Electronics N.V. (PHG) Enters Into Collaboration With Janssen Pharmaceutica N.V. To Develop New Handheld Blood Test To Support Care Of Patients With Neuropsychiatric Disorders 3/25/2015 1:56:23 PM
Galapagos (GLPG.BR) Ends Long-Running R&D Inflammation Pact With Janssen Pharmaceutica N.V. 3/17/2015 6:07:57 AM
EB Pharma Announces License Agreement For Investigational Drug, Tipifarnib From Janssen Pharmaceutica N.V. For Development In Hepatitis Delta Virus (HDV) Infection 12/23/2014 7:51:48 AM
Galapagos NV (GLPG.BR) Initiates Phase 1 Study With GLPG1690, Triggering €6.6 M Milestone In The Alliance With Janssen Pharmaceutica N.V. 7/1/2014 9:13:37 AM
Janssen Pharmaceutica N.V. To Present New Simeprevir Data At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 3/24/2014 9:49:06 AM
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014 9:59:54 AM
Jubilant BioSys Ltd. Announces Expansion Of Drug Discovery Alliance With Janssen Pharmaceutica N.V. 2/19/2014 7:14:37 AM
Janssen Pharmaceutica N.V. Unveils New Data On Xeplion® In Various Stages Of Schizophrenia 12/1/2013 10:02:42 PM
Galapagos NV (GLPG.BR) Initiates Phase 1 Trial as Part of Its Alliance With Janssen Pharmaceutica N.V. 7/2/2013 10:43:47 AM